Clincosm LogoSign in Get a demo

Abaloparatide and Pelvic Fracture Healing

Sponsor
Hospital for Special Surgery, New York (Other)
Overall Status
Recruiting
CT.gov ID
NCT04249232
Collaborator
Weill Medical College of Cornell University (Other), Icahn School of Medicine at Mount Sinai (Other), New York University (Other), Westchester Medical Center (Other)
78
Enrollment
4
Locations
2
Arms
38.4
Anticipated Duration (Months)
19.5
Patients Per Site
0.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a prospective randomized, double-blinded, placebo-controlled, phase 2, three-month study of the efficacy of abaloparatide in postmenopausal women and men ≥ 50 years of age with acute fractures of the pelvis (n=78). The primary outcome is CT image based evidence of fracture healing. The secondary aims are pain and physical performance measures at 3 months. This study will be extended with 9 months of open label abaloparatide to determine if any potential differences between the placebo and abaloparatide groups during the 3 months of treatment are evident and persist over time, even in patients who use abaloparatide after the three-month placebo controlled intervention.

Condition or Disease Intervention/Treatment Phase
  • Drug: Abaloparatide 80 micrograms per Pen dose
  • Drug: Placebo prefilled injector pen
 Phase 2

Detailed Description

By 2030 over 25% of the entire US population will be older than 65 years of age. Pelvic fracture rates are higher in women. Over 90% of pelvic fractures in patients >60 years are defined as osteoporosis related fractures. In a recent study in Germany, the rate of all first pelvic fractures in persons over 60 was 22.4 [95% CI 22.0-22.9] per 10,000 person-years. The incidence rate increases dramatically with age, from 5.4 and 3.8 per 10,000 person-years in women and men aged 65 to 69 years to 93.5 and 44.5 per 10,000 person-years in women and men aged 90 years and older, respectively. This is in agreement with studies in the US and Finland, also showing an increase in incidence of pelvic fractures with age. Pelvic fractures are most often a result of low-energy trauma, such as a fall from standing height. Pelvic fractures are the most relevant for this proposed randomized placebo-controlled study. This fracture is accompanied by severe pain, chronic immobility and loss of function and independence in the elderly. The current treatment strategy of pelvic fractures includes pain management, patient mobilization, and the prevention of complications associated with comorbid conditions. In a review of six studies with over 500 patients, the mean length of hospital stay was 13.4 days and the average 1-year mortality was 16.3%. Mortality rates in 1300 pelvic fracture patients were still elevated at 3 years. Pelvic fractures are associated with slow healing and a delayed return to full function and normal activity. Pelvic fractures consume substantial healthcare resources, and based on administrative claims data, they are one of the most costly osteoporosis related fractures. Un-healed fractures, occurring in one-third of pelvic fracture patients at 3 months, can cause continued pain and impact mobility. With aging of the population and expected concomitant increase in the incidence of pelvic fractures, there is a pressing need to find effective treatments that will accelerate healing. There are strong preclinical data, as well as clinical evidence, that administration of parathyroid hormone (PTH) receptor agonists may improve bone union, hasten fracture healing and improve physical function. In one nonrandomized, un-blinded study, 100% of pelvic fracture patients given 1-84PTH were healed within 12 weeks compared to 68% of the controls. However, there is not sufficient evidence at this time to recommend routine use of PTH receptor agonists for fracture healing. Pelvic fractures are ideal to study for the impact of abaloparatide on rate of fracture healing because there are no surgical repairs for the vast majority of the fractures. Prior studies of teriparatide on wrist fracture healing were limited and confounded by the increased prevalence of surgical fixation to treat these fractures. Strong evidence of pelvic fracture healing that may result from this study may not only have an impact on pelvic fractures but perhaps may indicate a potential use for other fractures as well.

In the proposed randomized, double blind, placebo controlled clinical trial in patients >50 years of age with acute pelvic fracture, the investigators plan to evaluate whether treatment with daily subcutaneous ABALOPARATIDE 80 mcg/day compared with placebo, in addition to standard treatment (pain management, bed rest and prevention of complications from comorbid conditions), is effective in accelerating fracture healing in women and men compared to standard treatment alone. The investigators hypothesize that development of a successful adjunctive therapy (ABALOPARATIDE) will accelerate radiographic evidence of fracture healing and speed functional recovery. If this hypothesis holds true, it would lead to a change in clinical practice and an improved quality of care for pelvic fracture patients. Evidence of an impact on the healing of pelvic fractures may also extend to a potential to improve healing of other osteoporosis-related fractures. In the planned trial the investigators will recruit women and men with acute pelvic fractures and address 3 specific aims over 3 months of treatment in a placebo controlled double blind study to determine if ABALOPARATIDE in addition to standard care versus placebo and standard care:

  1. Results in evidence of more complete cortical bridging at 3 months using focus CT to reduce radiation exposure from CT scans (primary outcome).

  2. Leads to a faster reduction in pain as assessed by both the Numeric Rating Scale and a reduction in the use of narcotics (secondary outcome).

  3. Leads more to a more rapidly improved functional outcome using measures to assess lower extremity function (Continuous Summary Physical Performance Score and Timed Up and Go- secondary outcomes).

Although the primary analysis will be based on data from 0 to 3 months, whether the benefit of ABALOPARATIDE on fracture healing wanes over time is unclear, making a longer follow-up important to extend knowledge on the persistence of early ABALOPARATIDE effect on these outcomes. Therefore, the investigators will extend this study with 9 months of open label ABALOPARATIDE to determine if any potential differences between the placebo and ABALOPARATIDE groups during the 3 months of treatment are evident and persist over time, even in patients who use ABALOPARATIDE after the three month placebo controlled intervention.

If ABALOPARATIDE can improve fracture healing, this study will have an impact on the treatment of persons with pelvic fracture who are not surgical candidates and often face severe pain, chronic immobility, and loss of function in the elderly. A positive finding of accelerated healing of pelvic fractures would also encourage study of ABALOPARATIDE for treatment of other osteoporotic fractures.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
78 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Parallel assignment with randomizationParallel assignment with randomization
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Quadruple
Primary Purpose:
Treatment
Official Title:
Abaloparatide Versus Placebo for Pelvic Fracture Healing - A Phase 2 Randomized Controlled Trial
Actual Study Start Date :
Sep 17, 2020
Anticipated Primary Completion Date :
Aug 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: abaloparatide prefilled syringe

Abaloparatide-SC is supplied as a liquid, 3120 micrograms per 1.56 milliliter (2000 mcg/mL) in a single patient multi-use prefilled pen. The prefilled pen delivers 30 doses of abaloparatide, each containing 80 mcg of abaloparatide in 40 microliters of a sterile, clear, colorless solution. To be administered subcutaneously daily.

Drug: Abaloparatide 80 micrograms per Pen dose
prefilled injector pen to deliver 80 micrograms daily subcutaneously
Other Names:
  • Tymlos

    		•
    Placebo Comparator: Placebo prefilled syringe

    For the placebo-SC a prefilled multi-use pen injector cartridge is designed to deliver 30 doses of placebo each in 40 microliters of sterile, clear, colorless solution to be administered subcutaneously daily.

    Drug: Placebo prefilled injector pen
    prefilled injector pen to deliver inactive solution daily subcutaneously
    Other Names:
  • placebo

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Efficacy for fracture healing- Measured by participant cortical bridging scores [3 months]

      Score for cortical bridging on a CT exam at 3 months in abaloparatide versus placebo groups.

    Secondary Outcome Measures

    1. Efficacy measure of participant pain score as assessed by the Numeric Rating Scale [8 weeks]

      Pain score measured by Numeric rating scale that uses a scale from 0 (no pain) to 10 (worst pain imaginable), the subject will report how intense their pain is now and how intense it was on average last week. This will be compared in the abaloparatide versus placebo groups.

    2. Efficacy measure of participant pain score as assessed by the Numeric Rating Scale [12 months]

      Pain score measured by Numeric rating scale that uses a scale from 0 (no pain) to 10 (worst pain imaginable), the subject will report how intense their pain is now and how intense it was on average last week. This will be compared over time in the abaloparatide versus placebo groups.

    3. Participant lower extremity function based on a score from the Continuous Summary Physical Performance Score. The measure of lower extremity physical function is an efficacy variable. [3 months]

      Physical function as an efficacy outcome using a continuous summary physical performance score based on a battery of tests, including walk speed, repeated chair stands and balance.

    4. Participant lower extremity function based on a score from the Continuous Summary Physical Performance Score. The measure of lower extremity physical function is an efficacy variable. [12 months]

      Physical function as an efficacy outcome using a continuous summary physical performance score based on a battery of tests, including walk speed, repeated chair stands and balance.

    5. Participant (percent) reporting narcotic use for pain [8 weeks]

      The use of narcotics will be collected at each visit and will be quantified into morphine equivalents. ABALOPARATIDE versus placebo groups will be compared for morphine equivalents.

    6. Efficacy measure of the time for participants to complete the Timed Up and Go Test. [3 months]

      The test begins by having the subject Stand up from the chair, walk to the line on the floor at a normal pace, turn, walk back to the chair at a normal pace and sit down again. The person administering the test will time the subject using a stopwatch. including walk speed, repeated chair stands and balance. In addition,Timed up and go score.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    50 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Postmenopausal women and men >50 years of age with acute pelvic fractures, occurring with minimal trauma, presenting to Mount Sinai, New York University, New York Presbyterian-Queens, Hospital for Special Surgery, or New York Hospital (Cornell Medical) within one month of the onset of symptoms.
    Exclusion Criteria:

    1. Persons unable to complete the NRS and other surveys based on assessment by the study doctor.

    2. Previously (prior to fracture) non-ambulatory subjects

    3. Exclusion criteria related to contraindication or intolerance to ABALOPARATIDE:

    4. Hypersensitivity to ABALOPARATIDE

    5. Patients with increased risk of osteosarcoma: Paget's disease, history of radiation treatment

    6. Patients with active hypercalcemia based on serum calcium above the upper limit of normal.

    7. Serum creatinine cannot be elevated more than 1.5 times above upper normal limit for age

    8. Current diagnosis of hyperparathyroidism and other metabolic bone disease including osteogenesis imperfecta

    9. Multiple Kidney stones (calcium oxalate) within the last 10 years or single kidney stone (calcium oxalate) within the last year. If stone type is not known, a 24-hour urine calcium determination can be performed; if not elevated, the patient does not require exclusion.

    10. Normal alkaline phosphatase levels will not be used as an entrance criterion because most fracture patients will have elevations due to the acute fracture. However, we will attempt to obtain lab tests from the period prior to fracture to determine if they were normal. If unexplained elevations in alkaline phosphatase (more than 1.5 times above the upper limit of normal) are found in labs prior to the fracture, we will exclude that subject.

    11. Diagnosis of metastatic cancer within the past 10 years; primary bone cancer or multiple myeloma at any time. For other primary active non-skin cancers (diagnosed within the last 5 years), the patient's oncologist should be consulted to determine participant eligibility.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 NYU Langone Health New York New York United States 10016
    2 Hospital for Special Surgery New York New York United States 10021
    3 Mount Sinai New York New York United States 10029
    4 Westchester Medical Center Valhalla New York United States 10595

    Sponsors and Collaborators

    • Hospital for Special Surgery, New York
    • Weill Medical College of Cornell University
    • Icahn School of Medicine at Mount Sinai
    • New York University
    • Westchester Medical Center

    Investigators

    • Principal Investigator: Jeri W Nieves, PhD, Hospital for Special Surgery, New York
    • Principal Investigator: Joseph Lane, MD, Hospital for Special Surgery, New York

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Jeri Nieves, PhD, Professor of Clinical Epidemiology and Senior Research Scientist, Hospital for Special Surgery, New York
    ClinicalTrials.gov Identifier:
    NCT04249232
    Other Study ID Numbers:
    • 2019-1978
    First Posted:
    Jan 30, 2020
    Last Update Posted:
    Jul 28, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Jeri Nieves, PhD, Professor of Clinical Epidemiology and Senior Research Scientist, Hospital for Special Surgery, New York
    abaloparatide
    Additional relevant MeSH terms:
    Fractures, Bone
    Hip Fractures
    Abaloparatide

    Study Results

    No Results Posted as of Jul 28, 2022